AVID-CC study (COVID-19)

• Research type

  Research Study

• Full title

  Adalimumab in COVID-19 to present respiratory failure in community care (AVID-CC): A randomised controlled trial

• IRAS ID

  287434

• Contact name

  Duncan Richards

• Contact email

  duncan.richards@ndorms.ox.ac.uk

• Sponsor organisation

  University of Oxford, Clinical Trials and Research Governance

• Eudract number

  2020-003628-18

• ISRCTN Number

  ISRCTN33260034

• Duration of Study in the UK

  1 years, 4 months, 28 days

• Research summary

  Summary of Research
  COVID-19 has infected millions of people and nearly 50,000 patients have died in the UK. The virus enters the body through the lungs and causes mild shortness of breath, cough and fever in the majority of cases. However, for reasons that remain unclear, in certain patients the disease can progress to severe respiratory failure, which may be fatal. This does not occur immediately but seems to progress over 7-10 days from first developing symptoms of COVID-19.

  The outcomes of residents of care homes have been particularly poor during this pandemic; infection rates have been high and many have died. There is a pressing need for an effective treatment to prevent respiratory failure or death in these patients.

  Across the UK,‘Hospital at Home’ teams deliver care to those in the community. These teams are there to provide healthcare to individuals at home (whether that is a private home or a residential care home) as an alternative to hospital admission. These teams work like a hospital ward team and have regular multi-disciplinary meetings where they discuss the patients they are looking after. The service is designed to give patients extra support so that they are not admitted to hospital. Hospital at home teams can include doctors, nurses, paramedics and health care assistants.

  The hospital at home care pathway therefore provides an unique means to reach patients in the community that are suspected of having COVID and starting to treat them early thus hopefully avoiding admission to hospital due to getting worse.

  The AVID-CC Trial will investigate whether giving a drug called Adalimumab (which is an anti-inflammatory, which blocks a chemical called Tumour Necrosis Factor (TNF)) to patients outside hospital with COVID-19 who are at increased risk of worsening can prevent progression to respiratory failure or death.

  Summary of Results
  Trial closed early without recruiting. No results to share

• REC name

  South Central - Berkshire Research Ethics Committee

• REC reference

  20/SC/0352

• Date of REC Opinion

  23 Sep 2020

• REC opinion

  Further Information Favourable Opinion